American Thoracic Society - Sanofi Investor Call slide image

American Thoracic Society - Sanofi Investor Call

sanofi Itepekimab: potent IL-33 blocker with sub-nanomolar affinity Smoke/pollutants Pathogens (virus & bacteria) IL-33 IL-33 IL-33 IL-33 IL-33 Neutrophil NK Cell Macrophage Th1 Basophil Mast cell Eosinophil Th2 ILC2 Itepekimab is under investigation and not yet approved by any regulatory agency. Clinical significance of the mechanism of action has not been established. 36 ATS Investor Call Potential to be best-in-class and first-in-class IL-33 biologic • • Binds to human IL-33 with high affinity (K-42PM) Amongst the longest half-life of anti-IL-33 class Amongst the best bioavailability of anti-IL-33 class • No immunogenicity signals
View entire presentation